Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2020

View Archived Issues

First-in-human study tests BI-764524 in diabetic macular ischemia

Akeso begins first-in-human study of AK-120 for atopic dermatitis

JS InnoPharm evaluates JSI-1187 for advanced solid tumors with MAPK pathway mutations

Placental attachment theory

CH-7233163: an EGFR inhibitor active against osimertinib-resistant EGFR-T790M/C797S mutations

Novel CTH-004 CAR T cells for the treatment of ovarian cancer

Machine learning, GWAS divide and conquer PCOS

TN1-006: a gene therapy-mediated cardiac reprogramming candidate with potential for MI treatment

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

CECSi cells show promising preclinical results for the treatment of bullous keratopathy

New gamma-secretase inhibitors identified at Roche

Lynk Pharmaceuticals patents Janus kinase inhibitors

Dual CACNA2D1/mu-opioid receptor ligands discovered at Esteve

Emerald Health Biotechnology Espana identifies monoglyceride lipase inhibitors

FDA approves IND for phase II study of antroquinonol in patients with COVID-19

Phase I study of DS-1062 expanded to include patients with TNBC

Menarini plans phase Ib/II study of MEN-1611 in metastatic colorectal cancer

FDA clears initiation of phase III trial of siltuximab for COVID-19-associated ARDS

Early positive data for BNT-162b1 vaccine candidate against SARS-CoV-2

Recruitment starts in phase II study of DUR-928 in COVID-19 with acute liver or kidney injury

European Commission approves canagliflozin label update

Promising efficacy of SJP-1602 in models of TNBC

RO-7297089 begins first-in-human study for relapsed or refractory multiple myeloma

Chinese phase I study evaluates TQB-3558 for solid tumors

European Commission approves Janssen's Ebola vaccine regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...